Sagimet Biosciences (SGMT) Preferred Stock Liabilities (2022 - 2023)

Sagimet Biosciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $214.6 million for Q2 2023.

• In Q2 2023, Preferred Stock Liabilities changed 0.0% year-over-year to $214.6 million; the TTM figure through Jun 2023 stood at $214.6 million (changed 0.0% YoY), while the FY2022 annual figure was $214.6 million, changed N/A from the prior year.
• Preferred Stock Liabilities was $214.6 million for Q2 2023 at Sagimet Biosciences, roughly flat from $214.6 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $214.6 million in Q2 2022 to a low of $214.6 million in Q2 2022.